First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV Testing
SINGAPORE, Feb. 21, 2024 /PRNewswire/ BD , a leading global medical technology company, today.
/PRNewswire/ The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com s offering. The.
Share this article
Share this article
FRANKLIN LAKES, N.J., May 13, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry s first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC.
The new claim allows laboratories and facilities to process self-collected samples via a BD diluent tube using the BD Onclarity™ HPV Assay on either the BD Viper™ LT or the BD COR™ System. The BD Viper™ LT is in use globally and the BD COR™ System, launched last year, is in use across Europe.
BD Onclarity™ HPV Assay 3-Well PCR Reagent Wells